



December 22, 2025

**National Stock Exchange of India Limited**  
Trading Symbol: **NETWORK18**

**BSE Limited**  
SCRIP CODE: **532798**

Through: NEAPS

Through: BSE Listing Centre

Dear Sirs,

**Sub: Newspaper clippings - Special Window for re-lodgement of transfer requests of physical shares**

We enclose herewith copies of the newspaper clippings on the subject published today i.e., December 22, 2025 in the following newspapers:

- Financial Express, all India Editions
- Navshakti, Mumbai Edition

For **Network18 Media & Investments Limited**

**Shweta Gupta**  
Company Secretary and Compliance Officer

Encl.: as above

**Network18 Media & Investments Limited**

(CIN - L65910MH1996PLC280969)

Regd. office: First Floor, Empire Complex, 414- Senapati Bapat Marg, Lower Parel, Mumbai-400013

T: +91 22 40019000 / 66667777 W: [www.nw18.com](http://www.nw18.com) E: [investors.n18@nw18.com](mailto:investors.n18@nw18.com)



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES, NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND "NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



SYMBIOTEC

SYMBIOTEC PHARMALAB LIMITED



(Please scan this QR code to view the Draft Red Herring Prospectus)

Symbiotec Pharmalab Limited (our "Company") was incorporated as "Symbiotec Pharmalab Private Limited" as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025 and a special resolution dated September 12, 2025 passed in the extraordinary general meeting of our Shareholders. Consequently the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre. For further details on the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 269 of the draft red herring prospectus dated December 19, 2025 ("DRHP").

Corporate Identity Number: U24232MP2002PLC015293; Website: www.symbiotec.com  
Registered and Corporate Office: 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India  
Contact Person: Sallil Jain, Company Secretary and Compliance Officer; Telephone: +91 731 667 6405; Email: secretarial@symbiotec.com

THE PROMOTERS OF OUR COMPANY: ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹21,800.00 MILLION ("OFFER"). THE OFFER COMPRISES A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹1,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING UP TO ₹20,300.00 MILLION, COMPRISING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹1,800.00 MILLION BY SATWANI HOLDINGS LLP (THE "PROMOTER SELLING SHAREHOLDER"), UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹12,500.00 MILLION BY ROSEWOOD INVESTMENTS AND UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹6,000.00 MILLION BY INDIA BUSINESS EXCELLENCE FUND – III (THE "INVESTOR SELLING SHAREHOLDERS"), AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDER, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE"). THE OFFER WILL CONSTITUTE [•]% OF THE POST-OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

IN ACCORDANCE WITH AND SUBJECT TO REGULATION 33 OF THE SEBI ICDR REGULATIONS, THE OFFER MAY INCLUDE A RESERVATION OF UP TO [•] EQUITY SHARES (OF FACE VALUE OF ₹2 EACH), AGGREGATING UP TO ₹[•] MILLION (CONSTITUTING UP TO 5% OF THE POST OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [•]% AND [•]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, MAY OFFER A DISCOUNT OF UP TO [•]% (EQUIVALENT TO ₹[•] PER EQUITY SHARE) TO THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING UNDER THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A FURTHER ISSUE OF SPECIFIED SECURITIES AS MAY BE PERMITTED UNDER APPLICABLE LAW, AT ITS DISCRETION, AGGREGATING UP TO ₹300.00 MILLION (THE "PRE-IPO PLACEMENT"), PRIOR TO THE FILING OF THE RED HERRING PROSPECTUS. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED ("SCRR"). THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THAT THE OFFER MAY BE SUCCESSFUL AND WILL RESULT IN THE LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND PROSPECTUS, AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

THE FACE VALUE OF THE EQUITY SHARE IS ₹2 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND, THE MINIMUM BID LOT AND THE EMPLOYEE DISCOUNT, IF ANY, WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF [•] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), AND ALL EDITIONS OF [•] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER), HINDI ALSO BEING THE REGIONAL LANGUAGE OF MADHYA PRADESH WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID / OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED FOR UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid / Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid / Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of one Working Day, subject to the Bid / Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid / Offer Period, if applicable, shall be disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks ("SCSBs"), Designated Intermediaries and the Sponsor Bank(s), as applicable.

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, the "QIB Portion", provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as under: (i) 33.33% for the domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which allocation will be made to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations. Any under-subscription in the reserved category specified in clause (ii) above may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the "Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIB Bidders (other than Anchor Investors) including Mutual Funds subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders (out of which one-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with an application size of more than ₹0.20 million and up to ₹1.00 million and two-thirds shall be reserved for Bidders with an application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category) and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account and UPI ID in case of UPI Bidders; as applicable, pursuant to which their corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For further details, see "Offer Procedure" on page 473 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated December 19, 2025 with the SEBI and the Stock Exchanges. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with the SEBI has been made available to the public for comments, if any, for a period of at least 21 days from the date of publication of public announcement in accordance with Regulation 26(2) of SEBI ICDR Regulations. The DRHP has been filed by hosting it on the website of the Company at www.symbiotec.com, website of the SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively and the websites of the BRLMs, i.e., JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfi.com, www.avendus.com, www.motilaloswalgroup.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Our Company hereby invites, the public to give comments on the DRHP filed with the SEBI and the Stock Exchanges with respect to disclosures made in the DRHP. The public is requested to send a copy of their comments to the SEBI, the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned below in relation to the Offer. All comments must be received by the SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer at their respective addresses mentioned below on or before 5.00 p.m. on the 21<sup>st</sup> day from the date of publication of this public announcement in accordance with Regulation 26(2) of SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 42 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus has been filed with the RoC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the DRHP. The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on the mainboard of BSE and NSE.

For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them, please see the section "Capital Structure" on page 112 of the DRHP. The liability of members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section "History and Certain Corporate Matters" on page 269 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
<b>JM Financial Limited</b> 7 <sup>th</sup> Floor, Chhatrapati Shivaji Maharaj Prasthadevi, Mumbai 400 025, Maharashtra, India Telephone: +91 22 6630 3030 E-mail: symbiotec ipo@jmfi.com Investor Grievance email: grievance.ltd@jmfi.com Website: www.jmfi.com Contact Person: Prachee Dhuri SEBI Registration No.: INM000010361	<b>Avendus Capital Private Limited</b> Platina Building, 9 <sup>th</sup> Floor, 901, Plot No C-59, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Telephone: +91 22 6648 0050 Email: symbiotec.ipo@avendus.com Investor grievance email: investor.grievance@avendus.com Website: www.avendus.com Contact person: Santhak Sawal/Shagun Lalwani SEBI Registration No: INM000011021	<b>Motilal Oswal Investment Advisors Limited<sup>A</sup></b> Motilal Oswal Tower, Rahimullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai – 400 025, Maharashtra, India Telephone: +91 22 7193 4380 E-mail: spl.ipo@motilaloswal.com Investor Grievance E-mail: moiapredressal@motilaloswal.com Website: www.motilaloswalgroup.com Contact Person: Kunal Thakkar/Vaibhav Shah SEBI Registration No.: INM000011005	<b>Nomura Financial Advisory and Securities (India) Private Limited</b> Ceejay House, Level 11, Plot F, Shiv Sagar Estate, Dr. Annie Besant Marg, Worli, Mumbai – 400 018, Maharashtra, India Telephone: +91 22 4037 4037 E-mail: symbiotecipo@nomura.com Investor Grievance E-mail: investor.grievances-in@nomura.com Website: www.nomuraholdings.com/company/group/asia/india/index.html Contact Person: Vishal Kanjani/Chirag Shah SEBI Registration No.: INM000011419	<b>MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)</b> C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Telephone: +91 810 811 4949 Email: symbiotecpharmalab.ipo@in.mpmf.mufg.com Investor grievance email: symbiotecpharmalab.ipo@in.mpmf.mufg.com Website: www.in.mpmf.mufg.com Contact person: Shanti Gopalkrishnan SEBI Registration No: INR000004058
COMPANY SECRETARY AND COMPLIANCE OFFICER				
Sallil Jain, 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India, Telephone: +91 731 667 6405; Email: secretarial@symbiotec.com				

<sup>A</sup>In compliance with the proviso to regulation 21A(1) and explanation (iii) to regulation 21A(1) of the SEBI Merchant Bankers Regulations, and regulation 23(3) of the SEBI ICDR Regulations, Motilal Oswal Investment Advisors Limited will be involved only in marketing the Offer. Motilal Oswal Investment Advisors Limited has signed the due diligence certificate and has been disclosed as a BRLM for the Offer.

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP

For Symbiotec Pharmalab Limited  
on and behalf of the Board of Directors  
Sd/-  
Sallil Jain  
Company Secretary and Compliance Officer

Place: Madhya Pradesh, India  
Date: December 19, 2025

Symbiotec Pharmalab Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated December 19, 2025 with the SEBI and the Stock Exchanges. The DRHP is available on the website of the Company at www.symbiotec.com, SEBI at www.sebi.gov.in, as well as on the websites of the BRLMs, i.e., JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfi.com, www.avendus.com, www.motilaloswalgroup.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 42 of the DRHP and the details set out in the Red Herring Prospectus, when filed. Any potential investors should not rely on the DRHP for making any investment decision.

This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) in the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to the private placement exemption set out in Section 4(a) of the U.S. Securities Act, and (b) outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.

Adfactors

**ASSAM ELECTRICITY GRID CORPORATION LIMITED**

**NOTICE**

The Assam State Load Despatch Centre. (SLDC), have filed Petition before the Hon'ble Assam Electricity Regulatory Commission (AERC) for approval of Truing up for FY 2024-25, Annual Performance Review for FY 2025-26 and Aggregate Revenue Requirement for FY 2026-27 of SLDC (Petition No: 23/2025).

The Hon'ble Commission has directed that any person who intends to file objection or comments in regard to proposed ARR of SLDC may do so by filing statement of objections or comments before the Secretary, Assam Electricity Regulatory Commission with copies of relevant documents and evidence in support thereof along with the affidavit as in Form – 2 of Assam Electricity Regulatory Commission (Conduct of Business) Regulations, 2004 as amended from time to time. Such objections or comments shall be submitted in soft copy to [gm.mpr@aegcl.co.in](mailto:gm.mpr@aegcl.co.in) and 5 (five) copies by speed post or in person which should reach the **Secretary, Assam Electricity Regulatory Commission, ASEB Campus, Sixth Mile, Dwarandhar, Guwahati-22** on or before **12-01-2026**. A copy of the Petition is also available on the website of the Hon'ble Commission [www.aerc.nic.in](http://www.aerc.nic.in) and [www.aegcl.co.in](http://www.aegcl.co.in).

Sd/- General Manager (M&PR),  
AEGCL, Bijulee Bhawan, Guwahati – 781 001

FORM A PUBLIC ANNOUNCEMENT (Regulation 14 of the Insolvency and Bankruptcy Board of India (Voluntary Liquidation) Regulations, 2017)	
FOR THE ATTENTION OF THE STAKEHOLDERS OF FARFETCH INDIA PRIVATE LIMITED	
1. Name of Corporate Person	FARFETCH INDIA PRIVATE LIMITED
2. Date of Incorporation of Corporate Person	20 April 2018
3. Authority under which Corporate Person is Incorporated/ Registered	ROC Delhi
4. Corporate Identity Number / Limited Liability Identity Number of Corporate Person	U74909DL2018FTC332854
5. Address of the Registered Office and Principal Office (if any) of Corporate Person	501 & 502, 5th Floor, Eros Corporate Tower, Nehru Place, South Delhi, New Delhi, Delhi, India, 110019
6. Liquidation Commencement Date of Corporate Person	19 December 2025
7. Name, Address, Email Address, Telephone Number and the Registration Number of the Liquidator	Name: Sudha Pravin Navandar Address: D 519-520, Neelkanth Business Park, Nathani Road, Vidyavihar West, Mumbai, 400086 Email ID Registered with IBB: <a href="mailto:sudha@pmco.in">sudha@pmco.in</a> Email ID for correspondence: <a href="mailto:liquidator.flpindia@gmail.com">liquidator.flpindia@gmail.com</a> Phone No: +91 9324351841 IP Registration No. IBB/PA-001/IP-PO0451/2017-2018/10794
8. Last Date for Submission of Claims	18 January 2026

Notice is hereby given that **Farfetch India Private Limited** has commenced voluntary liquidation on 19 December 2025.

The stakeholders of **Farfetch India Private Limited** are hereby called upon to submit a proof of their claims, on or before 18 January 2026, to the liquidator at the address/ email mentioned against item 7.

The financial creditors shall submit their proof of claims by electronic means only. All other stakeholders may submit the proof of claims in person, by post or by electronic means. Submission of false or misleading proofs of claim shall attract penalties.

Sd/-  
Sudha Pravin Navandar  
Liquidator  
Farfetch India Private Limited  
IBBI/PA-001/IP-PO0451/2017-2018/10794  
E-Mail ID Registered with IBB: [sudha@pmco.in](mailto:sudha@pmco.in)  
E-mail ID for correspondence: [liquidator.flpindia@gmail.com](mailto:liquidator.flpindia@gmail.com)  
Date: December 22, 2025, Place: Mumbai

**SUMEDHA**  
adding values to value

**Sumedha Fiscal Services Ltd.**  
CIN: L70101WB1989PLC047465  
**Registered & Corporate Office** : 6A Geetanjali, 8B, Middleton Street, Kolkata - 700071  
**Telephone Nos.**: 91 33 2229 8936 / 6758  
**Email ID**: [investors@sumedhafiscal.com](mailto:investors@sumedhafiscal.com)  
**Website**: [www.sumedhafiscal.com](http://www.sumedhafiscal.com)

**ATTENTION SHAREHOLDERS**  
**OPENING OF SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS FOR PHYSICAL SHARES**  
Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/ CIR/2025/97 dated July 02, 2025, to facilitate ease of investing for investors and to secure the rights of investors, a special window has been opened only for re-lodgment of transfer deeds, which were lodged prior to the deadline of April 01, 2019 and rejected / returned / not attended due to deficiency in the documents / process / or otherwise.

**Key Details:**  
**a) Who can re-lodge the transfer deeds?**  
Investors who lodged the transfer deeds prior to April 01, 2019 and rejected /returned / not attended due to deficiency in the documents/ process / or otherwise.  
**b) Period of re-lodgment**  
July 07, 2025 to January 06, 2026  
**c) How and whom to re-lodge?**  
Investors can re-lodge the request after rectifying the errors to our RTA - Maheshwari Datamatics Pvt. Ltd., 23, R. N. Mukherjee Road, 5th floor, Kolkata - 700001, Phone: 033 22435029 / 22482248, Email: [mdpldc@yahoo.com](mailto:mdpldc@yahoo.com)  
**d) What is the mode of transfer?**  
The securities that are re-lodged for transfer (including those requests that are pending with the listed Company / RTA, as on date) shall be issued only in demat mode. Due process shall be followed for such transfer-cum-demat requests.

The detailed circular is also available on the website of the Company at <https://www.sumedhafiscal.com/other-related-disclosure/important-circulars-sebi/>  
This is the twelfth and last publication issued in relation to the opening of the Special Window, as mandated under the provisions of the aforesaid circular.

**For Sumedha Fiscal Services Limited**  
**Dhwani Fatehpuria**  
Company Secretary & Compliance Officer  
Membership No. FCS 12817

**Date : 21.12.2025**  
**Place : Kolkata**

**Network 18**

**NETWORK18 MEDIA & INVESTMENTS LIMITED**  
CIN: L65910MH1996PLC280969  
Regd. Office: First Floor, Empire Complex, 414 - Senapati Bapat Marg, Lower Parel, Mumbai - 400 013.  
Tel: +91 22 6666 7777/ 4001 9000  
Website: [www.nw18.com](http://www.nw18.com) | Email: [investors.n18@nw18.com](mailto:investors.n18@nw18.com)

**NOTICE TO SHAREHOLDERS**  
**SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES**

In terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 02, 2025 on the captioned subject, please note that the Special Window for re-lodgement of transfer deeds of Network18 Media & Investments Limited will be open till January 6, 2026.

This facility is available only if the transfer deeds were lodged prior to April 1, 2019; and were rejected and returned due to deficiency in the documents.

In case you wish to avail this opportunity, please contact the Company's Registrar to an Issue and Share Transfer Agent i.e. KFin Technologies Limited (Unit: Network18 Media & Investments Limited) at their office at Selenium Tower-B, Plot No. 31 & 32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500 033, Toll Free No.1800-309-4001.

The shares that are re-lodged for transfer, if approved, will be issued only in demat mode and shall be under lock-in for a period of 6 months from the date of transfer.

For further information, please refer to the link for SEBI Circular <https://tinyurl.com/sebicj25> or send an email to [nwminvestor@kfinitech.com](mailto:nwminvestor@kfinitech.com)

**For Network18 Media & Investments Limited**  
Sd/-  
**Shweta Gupta**  
Company Secretary and Compliance Officer

**Place : Mumbai**  
**Date : December 22, 2025**

THE BUSINESS DAILY

FINANCIAL EXPRESS

Read to Lead

FOR DAILY BUSINESS





